Skip to main content
. 2019 Jul 22;10(9):1798–1804. doi: 10.1111/1759-7714.13149

Figure 1.

Figure 1

Clinical course of patients who had therapy discontinued due to irAEs. N represents nivolumab administration; P represents pembrolizumab administration. After discontinuation of ICIs, only two patients were given subsequent treatment.